Loading...

Essex Bio-Technology Limited

1061.HKHKSE
Healthcare
Drug Manufacturers - Specialty & Generic
HK$5.18
HK$-0.02(-0.38%)

Essex Bio-Technology Limited (1061.HK) Company Profile & Overview

Explore Essex Bio-Technology Limited’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Essex Bio-Technology Limited (1061.HK) Company Profile & Overview

Essex Bio-Technology Limited, an investment holding company, develops, manufactures, distributes, and sells biopharmaceutical products in the People's Republic of China and internationally. The company operates through Ophthalmic Products and Surgical Products segments. It researches and develops basic fibroblast growth factor products for the treatment of cellular proliferation, differentiation, and migration. The company offers Beifushu series, such as Beifushu eye drops, Beifushu eye gel, and Beifushu unit-dose eye drops; Tobramycin eye drops, Levofloxacin eye drops, and Sodium Hyaluronate eye drops, as well as Iodized Lecithin Capsules. It also provides Beifuji sprays and lyophilized powder, and Beifuxin gels for use in burn and scald wounds, acute wounds, surgical incisions, chronic wounds, skin grafting, and other applications. In addition, it offers ophthalmic and surgical products from third parties. Further, the company offers Carisolv dental caries removal gel; and Yi Xue An Granules. It has license agreements with Mitotech S.A. and Mitotech LLC. The company was founded in 1990 and is headquartered in Zhuhai, China.

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CEOMia Je Ngiam

Contact Information

86 75 6391 1188
No. 88 Keji 6th Road, Zhuhai

Company Facts

1,450 Employees
IPO DateJun 27, 2001
CountryCN
Actively Trading

Frequently Asked Questions

;